Company Profile

Lixte Biotechnology Holdingsinc Lixteis A Clinical Stage Publiclixtpharmaceutical Company Dedicated To Discovering Drugs For More Effective Treatments For Cancerlixte Has Identified Molecular Signaling Pathways Altered In Disease States And Designed Compounds That Can Safely Target Them In Animal Modelsthe Current Drug Portfolio Includes Inhibitors Of Protein Phosphatases That Are Critical To Cell Division And Dna Damage Repair And Inhibitors Of Protein Deacetylases That Regulate Pathways Of Gene Expression And Protein Degradationthe Phosphatase Inhibitors Enhance The Effectiveness Of Cytotoxic Anti Cancer Drugs In General As Well As Radiation Therapy Making Them Potentially Useful For The Treatment Of Manyif Not Allcancers In Combination With Existing Standard Chemotherapy Regimens And The Evolving Targeted Cytotoxic Therapies Of Personalized Cancer Medicinethe Lead Compound Lb 100 Is In Phase I Trial And Has The Potential To Be First In Classthe Deacetylase Inhibitors Have Anti Cancer Activity And In Model Systems Correct Enzymes Deficiencies Underlying Several Inborn Metabolic Diseases Including Gaucher And Von Hippel Lindau Disease And Neurofibromatosis Type 2Lixte S Cancer Drug Development Strategy Has Led To The Discovery Of Novel Compounds With The Potential To Be Therapeutically Useful Against Several Other Important But Seemingly Disparate Diseasesthe Phosphatase Inhibitors Are In Pre Clinical Development For Reducing The Extent Of Tissue Damage Following Strokeheart Attackand Septic Shockandthe Deacetylase Inhibitors For Prevention And Treatment Of Neurodegenerative Diseasestraumatic Brain Injuryand Topically For Fungal Dermatitis